作者: Debin Lu , Bing Chen , Ziwen Liang , Wuquan Deng , Youzhao Jiang
DOI: 10.1016/J.DIABRES.2010.12.010
关键词:
摘要: Aims: To identify better cells for the treatment of diabetic critical limb ischemia (CLI) and foot ulcer in a pilot trial. Methods: Under ordinary treatment, thelimbs 41type 2 patients with bilateralCLI were injected intramuscularly bone marrow mesenchymal stem (BMMSCs), marrow-derived mononuclear (BMMNCs), or normal saline (NS). Results: The healing rate BMMSC group was significantly higher than that BMMNCs at 6 weeks after injection (P = 0.022), reached 100% 4 earlier BMMNC group. After 24 follow-up, improvements perfusion induced by BMMSCs transplantation more significant those terms painless walking time 0.040), ankle-brachial index (ABI) 0.017), transcutaneous oxygen pressure (TcO2 )( P 0.001), magnetic resonance angiography (MRA) analysis 0.018).Therewas nosignificant differencebetween thegroupsin termsofpain reliefand amputation there no serious adverse events related to both cell injections. Conclusions: therapy may be tolerated effective increasinglowerlimbperfusionandpromotingfootulcerhealingindiabeticpatientswithCLI.